Drug: bismuth subsalicylate

Dark brown or black stools are common with use of bismuth subsalicylate. Tongue discoloration and constipation also may occur. Other side effects associated with bismuth subsalicylate include:
  • anxiety,
  • confusion,
  • depression,
  • headache,
  • slurred speech,
  • muscle spasms,
  • weakness,
  • hearing loss,
  • ringing in the ears,
  • Reye's syndrome,
  • abdominal pain,
  • nausea, and
  • vomiting.

Source: http://www.medicinenet.com

No

Source: http://www.medicinenet.com

  • Chewable tablets: 262, 525 mg
  • Oral suspension: 262 mg/15 ml, maximum strength 525 mg/15 ml
  • Caplets: 262 mg

Source: http://www.medicinenet.com

Bismuth subsalicylate products should be stored at room temperature, between 59 F to 86 F (15 C to 30 C).

Source: http://www.medicinenet.com

Over-the-counter treatment of nonspecific diarrhea in adults and adolescents (= 12 years):
  • Chewable tablets, caplets, liquids containing 262 mg/15 ml: 524 mg by mouth every 30-60 minutes as needed. Not to exceed 8 doses in 24 hours.
  • Liquids containing 525 mg/15 ml: 1050 mg by mouth every hour as needed. Not to exceed 4 doses in 24 hours.
  • Over-the-counter treatment of upset stomach, heartburn, indigestion, nausea, and related symptoms in adults and adolescents (= 12 years):
  • Chewable tablets, caplets, liquids containing 262 mg/15 ml: 524 mg by mouth every 30-60 minutes as needed. Not to exceed 8 doses in 24 hours.
  • Liquids containing 525 mg/15 ml: 1050 mg by mouth every hour as needed. Not to exceed 4 doses in 24 hours.
  • For the prevention of traveler's diarrhea due to Escherichia coli (E. coli) and viral infections in adults and adolescents (≥ 12 years):
  • 524 mg by mouth four times daily, starting 1 day before departure and continuing for 2 days after returning. Generally, treatment duration should not exceed 3 weeks.
  • For the eradication of helicobacter pylori as part of quadruple-drug regimen in adults and adolescents (≥ 12 years):
  • 525 mg by mouth 4 times daily.
The safety and effectiveness of bismuth subsalicylate use in children <12 years has not been established.

Source: http://www.medicinenet.com

Combining bismuth subsalicylate with sulfinpyrazone (Anturane) or probenecid is not recommended because bismuth subsalicylate may suppress the therapeutic effects of both drugs. Tetracycline and quinolone antibiotics may form insoluble complexes with bismuth subsalicylate. While bismuth subsalicylate should be avoided in patients taking these antibiotics if possible, separating administration by 2 hours may be sufficient to avoid this interaction. Bismuth subsalicylate should be used cautiously in patients taking methotrexate (Trexall). Bismuth subsalicylate is broken down to salicylic acid which is known to increase blood levels of methotrexate. Patients especially at risk for this interaction include those on high-dose methotrexate therapy, elderly patients, and patients with reduced kidney function.

Source: http://www.medicinenet.com

Bismuth subsalicylate is known to cross the placenta following oral administration. Use of salicylates during pregnancy has been associated with adverse effects in the fetus. Therefore use of bismuth subsalicylate during pregnancy should be avoided. Bismuth subsalicylate is classified as FDA pregnancy risk category C (adverse effects in animals but inadequate human data).

Source: http://www.medicinenet.com

Salicylates are excreted into human milk and can cause harm to the nursing infant. Bismuth subsalicylate is thought to be harmful to the nursing infant and should be avoided during breastfeeding. REFERENCE: FDA Prescribing Information.

Source: http://www.medicinenet.com

Health Services in Toronto

Drug Database Online

Welcome to WebHealthNetwork an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically bismuth subsalicylate. Find what medications you are taking today.